Bio-Techne Corporation
TECH
$77.29
$1.692.24%
| Weiss Ratings | TECH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Fair | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | C+ | |||
| Rating Factors | TECH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | Weak | |||
| Growth Index | Fair | |||
| Efficiency Index | Excellent | |||
| Solvency Index | Excellent | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | TECH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.11 | |||
| Price History | TECH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 23.21% | |||
| 30-Day Total Return | 8.52% | |||
| 60-Day Total Return | 9.92% | |||
| 90-Day Total Return | 1.71% | |||
| Year to Date Total Return | 0.76% | |||
| 1-Year Total Return | -1.43% | |||
| 2-Year Total Return | -19.26% | |||
| 3-Year Total Return | -30.16% | |||
| 5-Year Total Return | 59.88% | |||
| 52-Week High % Change | -30.31% | |||
| 52-Week Low % Change | 20.99% | |||
| Price | TECH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $89.91 | |||
| 52-Week Low Price | $51.79 | |||
| 52-Week Low Price (Date) | Nov 01, 2023 | |||
| 52-Week High Price (Date) | Jul 21, 2023 | |||
| Valuation | TECH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 9.76B | |||
| Enterprise Value | 10.18B | |||
| Price/Earnings (TTM) | 45.33 | |||
| Earnings Per Share (TTM) | 1.37 | |||
| Earnings Per Share Growth | -14.96% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 8.68 | |||
| Price/Book (Q) | 4.97 | |||
| Enterprise Value/Revenue (TTM) | 8.97 | |||
| Price | $77.29 | |||
| Enterprise Value/EBITDA (TTM) | 27.15 | |||
| Enterprise Value/EBIT | 38.32 | |||
| Market Cap Category | Mid Cap | |||
| Dividends and Shares | TECH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 160.06M | |||
| Dividend Yield | 0.52% | |||
| Div. Per Share (Most Recent) | $0.08 | |||
| Dividend Per Share (TTM) | $0.32 | |||
| Payout Ratio (TTM) | 22.48% | |||
| Dividend Per Share (Most Recent) | $0.08 | |||
| Company Info | TECH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 612 379 8854 | |||
| Address | 614 McKinley Place N.E. Minneapolis, MN 55413 | |||
| Website | www.bio-techne.com | |||
| Country | United States | |||
| Year Founded | 1976 | |||
| Profitability | TECH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | 23.40% | |||
| Profit Margin | 19.57% | |||
| Management Effectiveness | TECH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | 6.58% | |||
| Return on Equity | 11.83% | |||
| Income Statement | TECH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 1.14B | |||
| Total Revenue (TTM) | 1.14B | |||
| Revenue Per Share | $7.15 | |||
| Gross Profit (TTM) | 770.18M | |||
| EBITDA (TTM) | 378.26M | |||
| EBIT (TTM) | 268.02M | |||
| Net Income (TTM) | 224.16M | |||
| Net Income Avl. to Common (TTM) | 224.16M | |||
| Total Revenue Growth (Q YOY) | 0.37% | |||
| Earnings Growth (Q YOY) | -45.08% | |||
| EPS Diluted (TTM) | 1.37 | |||
| EPS Diluted Growth (Q YOY) | -45.16% | |||
| Balance Sheet | TECH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 135.65M | |||
| Cash Per Share (Q) | $0.85 | |||
| Total Current Assets (Q) | 590.64M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 1.96B | |||
| Current Ratio (Q) | 4.368 | |||
| Book Value Per Share (Q) | $12.50 | |||
| Total Assets (Q) | 2.73B | |||
| Total Current Liabilities (Q) | 135.23M | |||
| Total Debt (Q) | 555.70M | |||
| Total Liabilities (Q) | 767.19M | |||
| Total Common Equity (Q) | 1.96B | |||
| Cash Flow | TECH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -423.63M | |||
| Cash from Financing (TTM) | 116.73M | |||
| Net Change in Cash (TTM) | -34.55M | |||
| Levered Free Cash Flow (TTM) | 146.81M | |||
| Cash from Operations (TTM) | 276.43M | |||
